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Abstract
Introduction Studies in vitro reveal that endothelin-1 (ET-1)
activates the α  isoform of protein kinase C (PKC-α ) in cultures
of endothelial cells, thereby deranging cellular integrity. Sepsis
and endotoxemia are associated with increased plasma
concentrations of ET-1 that induce acute lung injury (ALI). We
recently reported that non-selective ET-1 receptor blockade
attenuates ALI in sheep by reducing the endotoxin-induced
increase in extravascular lung water index (EVLWI). The aim of
this study was to find out whether this attenuation is associated
with reduced translocation of PKC-α  from the cytosolic to the
membrane fraction of lung tissue homogenate.
Methods Seventeen awake, instrumented sheep were randomly
assigned to a sham-operated group (n = 3), a
lipopolysaccharide (LPS) group (n = 7) receiving an intravenous
infusion of Escherichia coli 15 ng/kg per min for 24 hours, and
a tezosentan group (n = 7) subjected to LPS and, from 4 hours,
an intravenous injection of tezosentan 3 mg/kg followed by
infusion at 1 mg/kg per hour for the reminder of the experiment.
Pulmonary micro-occlusion pressure (Pmo), EVLWI, plasma
concentrations of ET-1, tumor necrosis factor-a (TNF-a), and
interleukin-8 (IL-8) were determined every 4 hours. Western
blotting was used to assess PKC-α .
Results In non-treated sheep a positive correlation was found
between the plasma concentration of ET-1 and Pmo in the late
phase of endotoxemia (12 to 24 hours). A positive correlation
was also noticed between Pmo and EVLWI in the LPS and the
LPS plus tezosentan groups, although the latter was
significantly reduced in comparison with LPS alone. In both
endotoxemic groups, plasma concentrations of ET-1, TNF-α ,
and IL-8 increased. In the LPS group, the cytosolic fraction of
PKC-α  decreased by 75% whereas the membrane fraction
increased by 40% in comparison with the sham-operated
animals. Tezosentan completely prevented the changes in PKC-
α  in both the cytosolic and the membrane fractions,
concomitantly causing a further increase in the plasma
concentrations of ET-1, TNF-α , and IL-8.
Conclusion In endotoxemic sheep, ET-1 receptor blockade
alleviates lung injury as assessed by a decrease in EVLWI
paralleled by a reduction in Pmo and the prevention of activation
of PKC-α .
Introduction
Endothelin-1 (ET-1) has been identified as the most potent
vasoconstrictor peptide known so far [1,2]. Locally produced
ET-1 acts on three types of G-protein-coupled receptor: ETA,
ETB1, and ETB2 [3]. The ETA and ETB2 receptors are expressed
in vascular smooth muscle cells, whereas ETB1 is localized
mainly in the endothelium. Binding of ET-1 to ETA and ETB2
leads to vascular constriction, whereas ETB1 induces relaxa-
tion by releasing nitric oxide and prostacyclin [4]. In the lowest
concentration range, ET-1 mainly acts on the ETB1 receptor
[5].
ALI = acute lung injury; ET-1 = endothelin-1; EVLWI = extravascular lung water index; IL = interleukin; LPS = lipopolysaccharide; PKC = protein 
kinase C; Pmo = pulmonary capillary micro-occlusion pressure; TNF = tumor necrosis factor.Critical Care    Vol 9 No 3    Kuklin et al.
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In sepsis, endotoxin and other microbial products that are
released into the bloodstream trigger endothelial cells to the
enhanced generation of ET-1 causing local vasoconstriction
[6-9]. The effect of ET-1 is most prominent in the pulmonary
circulation where the ETA and ETB receptors are widely distrib-
uted [10,11]. Previous investigators have noticed that intrave-
nously infused ET-1 results in increased pulmonary artery
pressure and lung edema [12,13]. Moreover, in isolated rat
lungs in which the vasculature has been paralyzed, ET-1
enhances microvascular permeability, but the mechanisms
involved have not yet been settled [14].
Studies in vitro have shown that the binding of ET-1 to its
receptor might induce the activation of protein kinase C (PKC)
[15,16]. Activation of the α  isoform of PKC (PKC-α ) might
cause disturbances in the shape of the cells as well as of the
intercellular junctions. The latter changes might promote acute
lung injury (ALI) [17-19]. However, we are unable to determine
whether any study in vivo has tested whether PKC-α  is acti-
vated in endotoxin-induced ALI.
In sheep subjected to continuous infusion of endotoxin, we
recently found that the dual ETA and ETB receptor blocker
tezosentan precludes ALI as evaluated by improved gas
exchange and a partial reversal of the increases in pulmonary
vascular pressures and extravascular lung water index
(EVLWI) [9]. However, the mechanisms involved in the
tezosentan-induced reduction of EVLWI still remain obscure.
We speculate whether non-selective blockade of ET-1 recep-
tor by tezosentan alleviates ALI by dampening the activation of
PKC-α  and modulating inflammatory mediators such as tumor
necrosis factor-α  (TNF-α ) and interleukin-8 (IL-8).
The aim of the present study was twofold: first, to investigate
in sheep subjected to endotoxin-induced lung injury whether a
relationship exists between the plasma concentration of ET-1
and characteristics of ALI such as the increases in lung micro-
vascular pressure and extravascular lung water content, with
or without tezosentan; and second, to assess the effects of
tezosentan on the activation of PKC-α  in lung tissue in parallel
with changes in the plasma concentrations of TNF-α  and IL-8.
Methods
The present investigation is based partly on data from a previ-
ously published study from our group [9] that was approved by
the Norwegian Experimental Animal Board.
In brief, 17 yearling sheep were instrumented with a pulmonary
artery thermal dilution catheter introduced via an introducer in
the left external jugular vein, a thermo-dye dilution catheter
introduced via an introducer in the ipsilateral common carotid
artery, and a catheter in the left atrium, as described previously
[9].
Experimental protocol
The animals were randomly assigned to a sham-operated
group (n = 3), a group (n = 7) receiving an intravenous infusion
of Escherichia coli lipopolysaccharide (LPS) 15 ng/kg per min
for 24 hours (LPS group), and a group (n = 7) subjected to
LPS and, from 4 hours, an intravenous injection of tezosentan
3 mg/kg followed by infusion at 1 mg/kg per hour for the
reminder of the 24-hour experiment (LPS plus tezosentan
group). During the experiment, sheep had free access to food
and water.
EVLWI was assessed by the thermal-dye dilution method
(Cold Z-021; Pulsion Medical Systems, Munich, Germany).
Pulmonary micro-occlusion pressure (Pmo) was determined
every 4 hours, as described previously [20]. In brief, Pmo was
determined by advancing the Swan-Ganz catheter into the
occlusion position in a distal pulmonary artery with the balloon
deflated. The criteria for attainment of the micro-occlusion
position included: first, easy retrograde aspiration of blood
from the catheter; second, a pH, partial pressure of oxygen
(PO2) and carbon dioxide (PCO2) of aspirated blood consist-
ent with occlusion position, that is, partial pressure of oxygen
in occlusion position higher than arterial partial pressure of
oxygen (PmoO2 > PaO2) and partial pressure of carbon diox-
ide in occlusion position higher than arterial partial pressure of
carbon dioxide (PmoCO2 < PaCO2); third, micro-occlusion
pressure greater than proximal occlusion pressure; and fourth,
micro-occlusion pressure greater than left atrial pressure, with
true zero confirmed by connecting the left atrial catheter and
the Swan-Ganz catheter sequentially to the same fixed trans-
ducer. Blood for biochemical analysis was sampled at 0, 4, 12,
and 24 hours. After the sheep had been killed, lung samples
were taken and kept in liquid nitrogen for further analyses.
Western blotting
The activation of PKC-α  was assessed by translocation of
kinase from cytosolic and/or membrane fractions of lung tissue
extracts. In brief, lung tissue samples were homogenized (Pol-
ytron homogenizer, blade rotation speed 5,000 r.p.m.) in 1 ml
of ice-cold extraction buffer consisting of (in mmol/l): 250
sucrose, 1 EDTA, 1 EGTA, 20 Tris-HCl pH 7.5, 10 2-mercap-
toethanol, 20 dithiothreitol and 1 tablet of Complete™ EDTA-
free protease inhibitor cocktail per 10 ml. Crude extracts were
centrifuged at 200g to remove debris, followed by 100,000g
for 60 min at 4°C. The supernatant represented the cytosolic
fraction. The pellet was resuspended by sonication in 200 ml
of a similar buffer supplemented with 1% Triton X-100 and
centrifuged at 25,000g for 15 min at 4°C. The supernatant
was collected as the Triton X-100-soluble membrane fraction.
For SDS-PAGE, 10% polyacrylamide gels were loaded with
10 mg of protein per lane. After the end of electrophoresis,
proteins were electroblotted to nitrocellulose membranes.
Membranes were probed overnight with anti-PKC-α  primary
antibodies (Santa Cruz Biotechnology, Santa Cruz, CA, USA)
at 4°C and for 1 hour with sheep anti-rabbit horseradishAvailable online http://ccforum.com/content/9/3/R211
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peroxidase-conjugated secondary antibodies (Zymed, San
Francisco, CA, USA) at 22°C. Blots were incubated with
ChemiLucent detection kit (Chemicon, Temecula, CA, USA).
Immunopositive bands of PKC-α  were detected with a Kodak
Image Station 1000 (Kodak, Rochester, NY, USA) and densi-
tometry readings were taken for statistical analysis.
Biochemical measurements
The ET-1 plasma levels were measured by chemiluminescent
enzyme immunoassay (QuantiGlo QET00; R&D Systems, Min-
neapolis, MN, USA). Plasma levels of TNF-α  and of IL-8 were
determined with an Immulite instrument (Diagnostic Products
Corporation, Los Angeles, CA, USA).
Statistical analysis
Data were checked for normal distribution by the Kol-
mogorov–Smirnov test. The relationship between ET-1, Pmo,
and EVLWI was evaluated by regression analysis with the
Pearson correlation coefficient. Equality of regression lines
between the LPS and the LPS plus tezosentan groups was
tested by single multiple regression [21]. The detected relative
amounts of PKC-α  in the groups and tissue fractions were
compared by one-way analysis of variance. Plasma concentra-
tions of ET-1, TNF-α , and IL-8 were analyzed by analysis of var-
iance for repeated measurements. If F  was statistically
significant, Scheffe's test was used for post hoc intergroup
analysis. To evaluate differences within groups towards the
baseline value (time 0 hours), we used test of contrasts. We
regarded P < 0.05 as statistically significant.
Results
In sham-operated sheep, all variables remained unchanged
throughout the 24-hour experiments. During the first 12 hours
we found no significant correlation between the plasma con-
centration of ET-1 and Pmo in sheep subjected to LPS (Fig.
1a). In contrast, we found a positive correlation between these
variables beyond 12 hours (P < 0.01; Fig. 1b). A positive cor-
relation also existed between Pmo and EVLWI in the LPS and
the LPS plus tezosentan groups, as depicted in Fig. 2. How-
ever, tezosentan reduced the slope of the regression line com-
pared with LPS alone (P < 0.05; Fig. 2).
As shown in Fig. 3, extracts of lung tissue from sheep exposed
to LPS displayed a 75% reduction of the cytosolic fraction of
PKC-α  in comparison with samples from sham-operated ani-
mals (P < 0.05). The membrane fraction of PKC-α  simultane-
ously increased by 40% in the LPS group compared with
sham-operated sheep. Administration of tezosentan com-
pletely prevented the translocation of PKC-α  from the
cytosolic to the membrane fractions.
Figure 4 shows that after 4 hours of exposure to LPS, in par-
allel with the rise in ET-1, the plasma concentrations of TNF-α
and IL-8 increased compared with intragroup baseline and
sham-operated animals (P < 0.05). Notably, on cessation of
the experiment, plasma concentrations of ET-1, TNF-α , and IL-
Figure 1
Relationship between plasma concentration of endothelin-1 (ET-1) and  pulmonary micro-occlusion pressure (Pmo) in sheep Relationship between plasma concentration of endothelin-1 (ET-1) and 
pulmonary micro-occlusion pressure (Pmo) in sheep. (a) From 0 to 12 
hours of LPS infusion (r = -0.51, P = 0.12, n = 10); (b) from 12 to 24 
hours of LPS infusion (r = 0.75, P < 0.01, n = 9).
Figure 2
Relationship between extravascular lung water index (EVLWI) and pul- monary micro-occlusion pressure (Pmo) in endotoxemic sheep Relationship between extravascular lung water index (EVLWI) and pul-
monary micro-occlusion pressure (Pmo) in endotoxemic sheep. LPS 
alone (r = 0.73, P < 0.01, n = 42). LPS with tezosentan (r = 0.67, P < 
0.0001, n = 42).Critical Care    Vol 9 No 3    Kuklin et al.
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8 were significantly higher in the LPS plus tezosentan group
than with LPS alone (P < 0.05).
Discussion
The present study shows that during the late phase of endo-
toxemia in sheep (12 to 24 hours), the plasma concentration
of ET-1 is significantly correlated with the microvascular pres-
sure, whereas no such correlation was found during the early
phase. Moreover, we observed a significant and positive cor-
relation throughout the experiment between microvascular
pressure and EVLWI in both endotoxemic groups. Interest-
ingly, the regression line had a significantly lower slope in ani-
mals receiving tezosentan. To our knowledge, this is the first
study demonstrating that blockade of ET-1 receptors pre-
cludes endotoxin-induced changes in PKC-α  in cytosolic and
membrane fractions of lung tissue.
Pulmonary microvascular pressure and permeability are impor-
tant determinants of lung edema [22]. As reported previously
by our group and others, increases in EVLWI in animals
exposed to infusion of LPS are associated with enhanced pul-
monary microvascular pressure [9,23,24]. However, none of
these investigators have focused on the relationship between
the plasma concentration of ET-1 and the pulmonary microv-
ascular pressure. There is therefore no general agreement
about where in the course of illness, or how, ET-1 exerts its
action. One previous report suggests that ET-1 contributes
Figure 3
Protein kinase Cα  (PKC-α ) in sheep lung tissue homogenates detected  by Western blotting Protein kinase Cα  (PKC-α ) in sheep lung tissue homogenates detected 
by Western blotting. (a) In the cytosolic fraction; (b) in the membrane 
fraction. Results are means ± SEM. Groups were as follows: sham-
operated group (n = 3); lipopolysaccharide group (LPS; n = 4); LPS 
plus tezosentan group (n = 4). †P < 0.05 between sham-operated and 
LPS groups; ‡P < 0.05 between LPS and LPS plus tezosentan groups.
Figure 4
Plasma concentration of endothelin-1 (ET-1), tumor necrosis factor-α   (TNF-α ) and interleukin-8 (IL-8) Plasma concentration of endothelin-1 (ET-1), tumor necrosis factor-α  
(TNF-α ) and interleukin-8 (IL-8). Results are means ± SEM. Groups 
were as follows: sham-operated group (n = 3); lipopolysaccharide 
group (LPS; n = 7); LPS plus tezosentan group (n = 7). ND, not detect-
able. †P < 0.05 between sham-operated and LPS groups; ‡P < 0.05 
between LPS and LPS plus tezosentan groups; *P < 0.05 between 
sham-operated and LPS plus tezosentan groups; &P < 0.05 from t = 0 
hours in the LPS group; §P < 0.05 from t = 0 hours in the tezosentan 
group.Available online http://ccforum.com/content/9/3/R211
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directly to the severity of ALI by increasing the pulmonary
microvascular pressure from the first hours of endotoxemia
[25]. However, at variance with these results, we found that a
fairly strong correlation between the plasma concentration of
ET-1 and Pmo exists only in the late phase of endotoxemia.
This is also in accordance with investigators who argue that
thromboxane A2 is the dominating mediator of vasoconstric-
tion during the first hours of endotoxemia, whereas ET-1 is
responsible for vasoconstriction in the late phase [26-29].
The significantly positive correlation between Pmo and EVLWI
in endotoxemia, and the decrease in the relationship after
treatment with tezosentan, agrees fully with a recent investiga-
tion in endotoxemic pigs [30]. However, the beneficial effects
of ET-1 blockade cannot be explained solely by attenuation of
the endotoxin-induced increase in pulmonary artery pressure.
The declining slope of the regression line between Pmo and
EVLWI in tezosentan-treated animals indicates that additional
factors affecting lung fluid filtration might be active. A few
years ago, investigators found that ET-1 increases fluid filtra-
tion in isolated blood-perfused rat lungs pretreated with
papaverine to deprive the lungs of any vascular tone [14].
Because the ability of the lung microvascular pressure to
increase was precluded, the authors interpreted their findings
as a result of increased permeability. However, the exact
mechanisms involved still remain obscure.
PKC consists of a set of different isoenzymes: classical (α , β ,
γ ), novel (ε , δ , θ , η ), and atypical (ξ , λ ), of which only the clas-
sical isoforms are sensitive to changes in intracellular Ca2+
concentration [31]. Recent studies have shown that ET-1
stimulates the release of Ca2+ from the endoplasmic reticulum
and activates PKC-α  in the cell membrane [15-19]. After being
activated, PKC-α  has been shown to mediate the disruption of
vascular endothelial cadherin junctions [32]. Moreover, PKC-
α  activates myosin light chain kinase, which is involved in
endothelial cell gap formation and barrier dysfunction [33]. In
the lung vasculature, PKC-α -induced disruption might
derange the endothelial integrity [19]. We therefore speculate
that the increase in vascular permeability and the evolution of
ALI might be due to ET-1-induced activation of PKC-α  in the
cell membrane. We believe that blockade of ET-1 receptors,
resulting in a combination of reduced microvascular pressure
and decreased activation of PKC-α , is one of the main reasons
for the amelioration of ALI in the present study.
It is well established that infusion of LPS stimulates a release
of inflammatory mediators such as TNF-α , IL-8, and ET-1 [34-
36]. In contrast, ET-1 stimulates monocytes and macrophages
to release TNF-α  and IL-8 in its own right [37,38]. In the
present study, enhanced plasma concentrations of TNF-α , IL-
8, and ET-1 were found after 4 hours in both endotoxemic
groups. However, at the end of the experiments the plasma
concentrations of all three mediators were significantly higher
in tezosentan-treated animals than in animals given LPS alone.
The increases in ET-1 and TNF-α  are consistent with a previ-
ous investigation employing the endothelin receptor antago-
nist bosentan [39], but in contrast to that short-term study, we
exposed sheep to 24 hours of endotoxemia. According to
another recent study, ETB receptors in the lungs are involved
in the clearance of ET-1 from the circulation [40]. Conse-
quently, ET-1 receptor blockade prolongs ET-1 half-life in the
plasma and reportedly shifts tissue uptake from the lungs to
other organs [41]. In the present study, tezosentan increased
the plasma concentration of ET-1 to an extent that might have
enhanced the release of TNF-α  and IL-8 from the monocytes
and macrophages.
The present endotoxin-induced lung injury model in sheep is
not ideal for elucidating the effects of ET-1 receptor blockade
on permeability because microvascular pressure cannot be
deliberately changed. Further studies of ET-1 receptor block-
ade on permeability are therefore required in a more complex
experimental setting on intact animals or in isolated perfused
lungs.
Conclusion
In endotoxemic sheep, ET-1 plasma concentration is signifi-
cantly correlated with Pmo in the late phase. Moreover, Pmo
and extravascular lung water content demonstrate a positive
correlation from the first hours of endotoxin infusion. Blockade
of ET-1 receptors attenuates ALI by reducing the pulmonary
microvascular pressure and most probably also by decreasing
permeability secondary to reducing the activation of PKC-α .
However, further studies are needed to explain the exact
mechanisms behind the decrease in extravascular lung water
and the prevention of activation of PKC-α  after ET-1 receptor
blockade.
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